Elisa Agostinetto(@ElisaAgostinett) 's Twitter Profileg
Elisa Agostinetto

@ElisaAgostinett

MD, Medical Oncologist🇮🇹•Research Physician at @JulesBordet Institute in Brussels🇧🇪 Great interest in #BreastCancer and #ImmunoOncology

ID:405069305

calendar_today04-11-2011 20:24:17

888 Tweets

2,7K Followers

1,5K Following

OncoAlert(@OncoAlert) 's Twitter Profile Photo

Completely agree with our OncoAlert 🚨Faculty Ben Westphalen 🇩🇪

We have been seeing the same with the emergence of new accounts that are NOT adding to the conversation but rather are the same echo chambers we have been avoiding in Oncology SoMe

OncoAlert has always been and

account_circle
OncoAlert(@OncoAlert) 's Twitter Profile Photo

THE OncoAlert 🚨5K REGISTRATION at Saturday, June 1st at 7am (Chicago)
Start Hyatt Regency at McCormick Place , Chicago

Countries of Colleagues participating:
🇺🇸🇨🇦🇨🇭🇹🇷🇮🇹🇧🇪🇸🇪🇲🇽🇱🇧🇵🇹🇫🇷🇲🇦🇦🇹🇭🇺🇸🇰🇮🇳🇩🇪🇮🇪🇳🇿🇬🇭🇪🇸🇪🇸🇻🇳🇳🇵
oncoalert.m-pages.com/T8RKPR/the-onc…

A warm welcome to our

account_circle
Elisa Agostinetto(@ElisaAgostinett) 's Twitter Profile Photo

Nice work from KU Leuven🇧🇪 group showing that metastases of primary mixed no-special type and lobular have an exclusive lobular histology

Results come from the postmortem tissue donation program UPTIDER (NCT04531696)

OncoAlert

thebreastonline.com/article/S0960-…

account_circle
OncoAlert(@OncoAlert) 's Twitter Profile Photo

The OncoAlert🚨ROUND UP is OUT
Covering April 12-18, 2024

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

Covering:
✅Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma out on NEJM
nejm.org/doi/full/10.10…

✅Timing of Radiotherapy (RT) After

account_circle
Elisa Agostinetto(@ElisaAgostinett) 's Twitter Profile Photo

Out in npj Journals Breast:

The proportion of pts with an actionable alteration (AA) in serial cfDNA⬇️with time

AA in HR+/HER2- MBC inform the selection of 🎯therapies while cfDNA in TNBC or HER2+ MBC seems less effective in guiding treatment

OncoAlert
nature.com/articles/s4152…

account_circle
OncoAlert(@OncoAlert) 's Twitter Profile Photo

The OncoAlert🚨NEWSLETTER OUT‼️
Covering April 12-18, 2024

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

COVERING
✅NEW Prostate guidelines European Association of Urology (EAU)
✅The Lancet Commission
✅1st line Pembro & cemiplimab in🫁 🧪
✅RADICALS RT ☢️in

account_circle
OncoAlert(@OncoAlert) 's Twitter Profile Photo

its said that if you want to go fast go alone and
if you want to go far, go together

Our deepest gratitude to OUR 🚨PARTNERS
STRONGER TOGETHER‼️

ASTRO 🇺🇸
European Cancer Organisation 🇪🇺
American Cancer Society 🇺🇸Journals
➡️ACS Journal Cancer CA: A Cancer Journal for Clinicians 🇺🇸
MASCC 🌐
ABC Global Alliance

account_circle
OncoAlert(@OncoAlert) 's Twitter Profile Photo

The The Lancet Breast Cancer Commission's mission:

To Close the🌐global equity gap in care through prevention, personalized treatment, inclusion, collaboration, cost awareness, and patient empowerment‼️

Charlotte Coles PhD Wanda (Wanyuan) Cui, MD Reshma Jagsi, MD

The @TheLancet Breast Cancer Commission's mission: To Close the🌐global equity gap in #breastcancer care through prevention, personalized treatment, inclusion, collaboration, cost awareness, and patient empowerment‼️ Charlotte Coles PhD @CuiWanda, MD @reshmajagsi, MD
account_circle
OncoAlert(@OncoAlert) 's Twitter Profile Photo

The 🚨Results
After the Publication of NATALEE in NEJM We Asked our Colleagues: Do You Consider Ribo+ET in Early Practice Changing? These were the results:

40% Not Practice Changing
-Most found NO clinical Significance
25% Found it Practice

account_circle
Elisa Agostinetto(@ElisaAgostinett) 's Twitter Profile Photo

Free access to our editorial in Annals of Oncology at the link⬇️

The role of adjuvant pembro is unclear, as KEYNOTE-522 did not foresee a randomisation at surgery

It’s likely that adjuvant pembro has a lower impact compared to neoadj pembro

OncoAlert

authors.elsevier.com/c/1iw3x3I2OQif…

Free access to our editorial in @Annals_Oncology at the link⬇️ The role of adjuvant pembro is unclear, as KEYNOTE-522 did not foresee a randomisation at surgery It’s likely that adjuvant pembro has a lower impact compared to neoadj pembro @OncoAlert authors.elsevier.com/c/1iw3x3I2OQif…
account_circle